Medscape

HER2 Positive, Low, Ultralow: What Testing Means in the ADC Era

Drs Kathy Miller and Sunil Badve discuss how HER2 testing has evolved over time as the need for that clinical testing has shifted, including assay limits, biology, and clinical impact.

Avacta upbeat on preCISION comparative study

Avacta Therapeutics said on Tuesday that new preclinical analysis indicated its proprietary 'preCISION' tumour-activated delivery platform could offer pharmacokinetic advantages over the marketed ...

Avacta's pre|CISION Mechanism for Payload Delivery Shows Key Advantages Compared to an Antibody Drug Conjugate in Innovative AI-Driven Analysis

Experimental data from FAP-Exd (AVA6103) demonstrates a more favorable profile compared to the marketed Antibody Drug Conjugate (ADC) ...
Pharmabiz

EMA validates Type II Variation marketing application for Enhertu as post-neoadjuvant treatment for patients with HER2 positive earlybreast cancer

EMA validates Type II Variation marketing application for Enhertu as post-neoadjuvant treatment for patients with HER2 positive earlybreast cancer: Tokyo Saturday, February 21, 20 ...